Business · 10/12/2025Updated: 10/17/2026 · 1 min read
FDA Issues Final Guidance on Promotional Labeling and Advertising for Prescription Biological Products
The FDA has released a final guidance document addressing promotional labeling and advertising considerations for prescription biological products, biosimilar products, and interchangeable biosimilar products, providing clarity for manufacturers and industry firms.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →